Plasma Proteomic Signatures for Early Risk Stratification Across Cardiovascular‐Kidney‐Metabolic Stages 0–2
Authors' conclusion
In early-stage CKM, plasma proteomic signatures captured preclinical molecular risk and improved prognostic discrimination beyond conventional clinical factors.
Study context
- Population
- UK Biobank participants with cardiovascular-kidney-metabolic (CKM) stages 0–2 and measurements of 2920 plasma proteins
- Participants
- 43,709 participants
- Outcome
- Protein associations with 11 incident outcomes and incremental prediction beyond clinical model
Methodological detailsUK Biobank, multivariable Cox models, repeated internal validation
- UK Biobank
- Multivariable Cox models
- Repeated internal validation
Main finding
As reported in the abstract
- Proteins with directionally concordant associations across all 11 outcomes
- 157
- Positive associations
- 155
- Inverse associations
- 2
- ΔC-index, outcome-specific proteomic signatures beyond clinical model
- 0.024-0.070
- ΔC-index, exploratory recurrent 12-protein panel
- 0.018-0.052
Observational data: associations, not effects.
Original publication
Plasma Proteomic Signatures for Early Risk Stratification Across Cardiovascular‐Kidney‐Metabolic Stages 0–2. Diabetes Obes Metab. Published 30 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →